Donna Gustafson, a 72-year-old Florida resident, was diagnosed with pancreatic cancer after a 22-hour journey from Florida to Australia. She joined a clinical trial exploring the use of personalized messenger RNA vaccines for cancer, a form of immunotherapy known as immunotherapy. The vaccines are personalized for each individual using genetic material taken from their unique tumor cells. After receiving nine doses of the vaccine, Gustafon and six others who responded, along with two of the eight people who did not respond, remained alive six years after treatment. The results of the Phase 1 clinical trial were published last year, but the six-year follow-up period shows that it may lead to longer life expectancy.